After a Sanofi-Aventis (SNY -4.9%) drug fails at an experimental trial to help breast cancer...

|About: Sanofi (SNY)|By:, SA News Editor

After a Sanofi-Aventis (SNY -4.9%) drug fails at an experimental trial to help breast cancer patients live longer, a tumble for Myriad Genetics (MYGN -10.2%), which makes a test that helps identify which patients could benefit from the SNY treatment.